Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 (everolimus) for SEGA associated with tuberous sclerosis complex
2007-006997-27Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subependymal giant cell astrocytoma (SEGA) and tuberous sclerosis complex (TSC) comparing RAD001 (everolimus) with Placebo (2 arms). Primary endpoint: SEGA response rate. Started May 2009; status: completed.
02
Drugs
everolimus
03
Conditions
subependymal giant cell astrocytoma (SEGA)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2007-006997-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006997-27.